Lumacaftor Plus Ivacaftor Combination
VX12-809-105
Phase 3 small_molecule completed
Quick answer
Lumacaftor Plus Ivacaftor Combination for Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation is a Phase 3 program (small_molecule) at Vertex Pharmaceuticals (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Vertex Pharmaceuticals (Ireland) Limited
- Indication
- Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed